Sign In
Buy ABCL
$5.72
-0.410 (-6.69%)
At Close: Jun 03, 2026
AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript
12:23am, Saturday, 22'nd Nov 2025
AbCellera Biologics Inc. ( ABCL ) Jefferies London Healthcare Conference 2025 November 20, 2025 8:00 AM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Presentation Unknown Anal
AbCellera Appoints Dr. Stephen Quake to its Board of Directors
09:00am, Monday, 10'th Nov 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Stephen Quake to its Board of Directors.
AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript
07:16pm, Friday, 07'th Nov 2025
AbCellera Biologics Inc. ( ABCL ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Tryn Stimart - Chief Legal Officer, CCO, Compliance Officer, Corporate Secretary & Privacy Off
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates
06:46pm, Thursday, 06'th Nov 2025
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.17 per share a year ago.
AbCellera Reports Q3 2025 Business Results
04:05pm, Thursday, 06'th Nov 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2025 Business Results.
AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
04:05pm, Tuesday, 07'th Oct 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in November and December 2025.
AbCellera Biologics: Entering Growth Phase After A Pause
07:35am, Monday, 06'th Oct 2025
AbCellera Biologics is poised for long-term growth as its clinical manufacturing facility nears completion, enabling in-house drug development and contract manufacturing revenue. ABCL's strategic pivo
Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?
10:41am, Tuesday, 30'th Sep 2025
Here is how AbCellera Biologics Inc. (ABCL) and Astrazeneca (AZN) have performed compared to their sector so far this year.
AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
04:05pm, Monday, 29'th Sep 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025.
AbCellera Biologics Inc. (ABCL) is a Great Momentum Stock: Should You Buy?
01:01pm, Monday, 29'th Sep 2025
Does AbCellera Biologics Inc. (ABCL) have what it takes to be a top stock pick for momentum investors? Let's find out.
AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
09:07am, Wednesday, 10'th Sep 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer.
AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
09:00am, Wednesday, 27'th Aug 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575.
AbCellera to Participate at Upcoming Investor Conferences in September
04:05pm, Tuesday, 12'th Aug 2025
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Participate at Upcoming Investor Conferences in September.
AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript
07:48pm, Thursday, 07'th Aug 2025
AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Andrew Booth - Chief Financial Officer Carl L.G. Hansen - CEO, President & Chair
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates
07:20pm, Thursday, 07'th Aug 2025
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.13 per share a year ago.
